CRISPR knockout rat cytochrome P450 3A1/2 model for advancing drug metabolism and pharmacokinetics research

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Lu, Jian ^a   Shao, Yanjiao ^a   Qin, Xuan ^a   Liu, Daozhi ^a   Chen, Ang ^a   Li, Dali ^a   Liu, Mingyao ^a,b   Wang, Xin ^a  

^a EAST CHINA NORMAL UNIVERSITY   (China)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYP3A1 PROTEIN, RAT; CYP3A2 PROTEIN, RAT; CYTOCHROME P450 3A; ISOPROTEIN; NIFEDIPINE;

ANIMAL; CRISPR CAS SYSTEM; DEFICIENCY; FEMALE; GENETICS; GENOTYPE; HALF LIFE TIME; LIVER; LIVER MICROSOME; MALE; METABOLISM; PATHOLOGY; PHENOTYPE; RAT; SMALL INTESTINE; SPRAGUE DAWLEY RAT;

ANIMALS; CRISPR-CAS SYSTEMS; CYTOCHROME P-450 CYP3A; FEMALE; GENOTYPE; HALF-LIFE; INTESTINE, SMALL; LIVER; MALE; MICROSOMES, LIVER; NIFEDIPINE; PHENOTYPE; PROTEIN ISOFORMS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 85013435911     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep42922     Document Type: Article

References (37)

1. Paine, M. F. et al. The human intestinal cytochrome P450 "pie". Drug Metab. Dispos. 34, 880-886 (2006).
2. Guengerich, F. P. Cytochrome p450 and chemical toxicology. Chem. Res. Toxicol. 21, 70-83 (2008).
3. van Herwaarden, A. E. et al. Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J. Clin. Invest. 117, 3583-3592 (2007).
4. Martignoni, M., Groothuis, G. M. & de Kanter, R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin. Drug Metab. Toxicol. 2, 875-894 (2006).
5. Zanger, U. M. & Schwab, M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther. 138, 103-141 (2013).
6. Gonzalez, F. J. Role of gene knockout and transgenic mice in the study of xenobiotic metabolism. Drug Metab. Rev. 35, 319-335 (2003).
7. Scheer, N. et al. Deletion of 30 murine cytochrome p450 genes results in viable mice with compromised drug metabolism. Drug Metab. Dispos. 42, 1022-1030 (2014).
8. Shao, Y. et al. CRISPR/Cas-mediated genome editing in the rat via direct injection of one-cell embryos. Nat. Protoc. 9, 2493-2512 (2014).
9. Lindblad-Toh, K. Genome sequencing: three's company. Nature 428, 475-476 (2004).
10. Ma, Y. et al. Heritable multiplex genetic engineering in rats using CRISPR/Cas9. PLoS One 9, e89413 (2014).
11. Sternberg, S. H., Redding, S., Jinek, M., Greene, E. C. & Doudna, J. A. DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. Nature 507, 62-67 (2014).
12. Wang, X. et al. Characterization of novel cytochrome P450 2E1 knockout rat model generated by CRISPR/Cas9. Biochem. Pharmacol. 105, 80-90 (2016).
13. Mali, P., Esvelt, K. M. & Church, G. M. Cas9 as a versatile tool for engineering biology. Nat Methods 10, 957-963 (2013).
14. Li, D. et al. Heritable gene targeting in the mouse and rat using a CRISPR-Cas system. Nat. Biotechnol. 31, 681-683 (2013).
15. Pattanayak, V. et al. High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat. Biotechnol. 31, 839-843, (2013).
16. Fu, Y. et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat. Biotechnol. 31, 822-826 (2013).
17. Ran, F. A. et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154, 1380-1389 (2013).
18. Furge, L. L. & Guengerich, F. P. Cytochrome P450 enzymes in drug metabolism and chemical toxicology: An introduction. Biochem. Mol. Biol. Educ. 34, 66-74 (2006).
19. Ghanayem, B. I., Wang, H. & Sumner, S. Using cytochrome P-450 gene knock-out mice to study chemical metabolism, toxicity, and carcinogenicity. Toxicol. Pathol. 28, 839-850 (2000).
20. Vignati, L. et al. An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics. Toxicology 216, 154-167 (2005).
21. Capecchi, M. R. Gene targeting in mice: functional analysis of the mammalian genome for the twenty-first century. Nat Rev Genet 6, 507-512, (2005).
22. Chu, X. et al. Characterization of multidrug resistance 1a/P-glycoprotein knockout rats generated by zinc finger nucleases. Mol. Pharmacol. 81, 220-227 (2012).
23. Hashimoto, M. et al. Knockout of mouse Cyp3a gene enhances synthesis of cholesterol and bile acid in the liver. J. Lipid Res. 54, 2060-2068 (2013).
24. Hashimoto, M. et al. Cyp3a deficiency enhances androgen receptor activity and cholesterol synthesis in the mouse prostate. J. Steroid Biochem. Mol. Biol. 163, 121-128 (2016).
25. van Waterschoot, R. A. et al. Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes. Mol. Pharmacol. 73, 1029-1036 (2008).
26. Qin, X., Liu, M. & Wang, X. New insights into the androgen biotransformation in prostate cancer: A regulatory network among androgen, androgen receptors and UGTs. Pharmacol. Res. 106, 114-122 (2016).
27. Khan, A. A. et al. Comparison of effects of VDR versus PXR, FXR and GR ligands on the regulation of CYP3A isozymes in rat and human intestine and liver. Eur. J. Pharm. Sci. 37, 115-125 (2009).
28. Matsubara, T. et al. Isolation and characterization of a new major intestinal CYP3A form, CYP3A62, in the rat. J. Pharmacol. Exp. Ther. 309, 1282-1290 (2004).
29. Streetman, D. S., Bertino, J. S. Jr. & Nafziger, A. N. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10, 187-216 (2000).
30. Emoto, C. & Iwasaki, K. Relative roles of CYP2C19 and CYP3A4/5 in midazolam 1′ -hydroxylation. Xenobiotica 37, 592-603 (2007).
31. Hasegawa, M. et al. Investigation of drug-drug interactions caused by human pregnane X receptor-mediated induction of CYP3A4 and CYP2C subfamilies in chimeric mice with a humanized liver. Drug Metab. Dispos. 40, 474-480 (2012).
32. Wang, X. & Yeung, J. H. Effects of Salvia miltiorrhiza extract on the liver CYP3A activity in humans and rats. Phytother. Res. 25, 1653-1659 (2011).
33. Wang, X., Cheung, C. M., Lee, W. Y., Or, P. M. & Yeung, J. H. Major tanshinones of Danshen (Salvia miltiorrhiza) exhibit different modes of inhibition on human CYP1A2, CYP2C9, CYP2E1 and CYP3A4 activities in vitro. Phytomedicine 17, 868-875 (2010).
34. Nagai, K., Suzuki, S., Yamamura, A. & Konishi, H. Change in pharmacokinetic behavior of intravenously administered midazolam due to increased CYP3A2 expression in rats treated with menthol. Biopharm. Drug Dispos. 36, 174-182 (2015).
35. Choi, J. S., Choi, I. & Choi, D. H. Effects of pioglitazone on the pharmacokinetics of nifedipine and its main metabolite, dehydronifedipine, in rats. Eur. J. Drug Metab. Pharmacokinet. 41, 231-238 (2016).
36. Cheng, Z. Y. et al. Contribution of baicalin on the plasma protein binding displacement and CYP3A activity inhibition to the pharmacokinetic changes of nifedipine in rats in vivo and in vitro. PLoS One 9, e87234 (2014).
37. Chen, A., Zhou, X., Tang, S., Liu, M. & Wang, X. Evaluation of the inhibition potential of plumbagin against cytochrome P450 using LC-MS/MS and cocktail approach. Sci. Rep. 6, 28482 (2016).